D-0651-2024 Class II Ongoing

Recalled by ProRx LLC — Exton, PA

FDA drug recall D-0651-2024 was initiated by ProRx LLC on Aug 22, 2024 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is ongoing. Affected quantity: 37 vials.

Recall details

Product Type
Drugs
Report Date
Sep 11, 2024
Initiation Date
Aug 22, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
37 vials

Product description

Tirzepatide 2 mL (10 mg/mL) and 20 mg/mL, 2mL Multidose SC Injection vials, Compounded Rx Product, ProRx 267-565-7008, NDC 84139-210-01

Reason for recall

Lack of Assurance of Sterility

Distribution pattern

Nationwide in the USA

Code information

Lot # ProRx040924-1, BUD 10/08/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0651-2024
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0651-2024. Report a data issue: hello@regdatalab.com.